Compare Invesco DB Agriculture Fund (DBA) vs Eli Lilly And Co (LLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco DB Agriculture Fund vs Eli Lilly And Co — how do they compare? Invesco DB Agriculture Fund trades at $28.35 (market cap $1.33B), while Eli Lilly And Co trades at $1,166.49 (market cap $1.06T). The key difference: Eli Lilly And Co is far larger — about 797× Invesco DB Agriculture Fund's market cap, and Eli Lilly And Co pays a 0.58% dividend while Invesco DB Agriculture Fund pays none. Which is the better fit depends on your goals — on Pluang, investors hold Invesco DB Agriculture Fund for 24 Days and Eli Lilly And Co for 93 Days on average.
| DBA | LLY | |
|---|---|---|
Market Cap | $1.33B | $1.06T |
Volume | 991,157 | 2,297,239 |
52-Week High | $29.49 | $1.28K |
52-Week Low | $25.44 | $799.57 |
Typical Hold Time | 24 Days | 93 Days |
Sector | — | Health |
Enterprise Value | — | $1.11T |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DBA (Invesco DB Agriculture Fund ETF) trades at $28.49, down 1.25% today but maintains strong YTD performance with 12.4% returns. The technical outlook remains bullish with moving averages signaling strength, though oscillators show neutral momentum. Recent news highlights agricultural ETF outperformance driven by weather risks and geopolitical tensions supporting commodity prices.
The fund's diversified agricultural futures exposure and 3.25% yield provide defensive characteristics amid market volatility. Key risks include high expense ratios (0.85%) and commodity price sensitivity. Analyst sentiment is mixed with Seeking Alpha maintaining a Hold rating while noting bullish consolidation near all-time highs since 2020.
Eli Lilly (LLY) trades at $1,169.93, up 1.07% on the day, with a bullish technical signal and strong fundamental momentum. The company reported robust earnings beats in recent quarters, with Q2 2026 EPS of $8.38 exceeding the $6.40 estimate. Revenue surged to $65.18 billion in 2025, driving a net income margin of 33.53%. Positive news flow highlights promising pipeline updates in weight-loss and diabetes drugs, reinforcing growth prospects.
Outlook remains favorable given dominant market position and innovation pipeline, though high valuation multiples pose a risk. Analyst consensus is strongly bullish with a $1,340 price target. Key risks include competitive pressures and execution challenges in scaling production to meet demand for blockbuster therapies.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Invesco DB Agriculture Fund
The index, which is comprised of one or more underlying commodities ("index commodities"), is intended to reflect the agricultural sector. The fund pursues its investment objective by investing in a portfolio of exchange-traded futures.
Read more on DBA →About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →
